Shots:
- Mission Therapeutics has reported the divestment of its P-II-ready asset MTX652, to Dimerix for initial development in Acute Kidney Injury (AKI)
- As per the deal, Mission will receive ~$292M in upfront, development & commercial milestones, plus up to double-digit tiered royalties on global net sales
- The divestment aligns with Mission’s strategy to maximize its USP30 platform by partnering its assets with developers best positioned to advance it in its therapeutic area
Ref: Globenewswire | Image: Mission Therapeutics & Dimerix | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us atconnect@pharmashots.com
